Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
$103.63-15.72%
报价 2026-11-06
市值
$11.76B
EV
$14.21B
PE (TTM)
29.3x
预期 PE (FY2026)
12.0x
52 周区间距高点 -21.0%
$61.63$131.18
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| HALOHalozyme Therapeutics, Inc. | $11.76B | -15.7% | +27.0% | 78.2% | 29.3x | 20.9x | 15.2x | |
| JAZZJazz Pharmaceuticals plc | $15.07B | +3.3% | – | 88.2% | – | 109.6x | – | |
| HSICHenry Schein, Inc. | $9.59B | +0.9% | +5.8% | 31.8% | 24.9x | 12.7x | 17.8x | |
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| CORTCorcept Therapeutics Incorporated | $7.87B | +1.6% | +19.7% | 98.3% | 218.0x | 422.2x | 114.6x | |
| RYTMRhythm Pharmaceuticals, Inc. | $7.73B | +6.9% | +57.7% | 88.2% | – | – | – | |
| ABVXAbivax S.A. | $7.5B | +1.8% | – | 0% | – | – | – | |
| CYTKCytokinetics, Incorporated | $7.46B | -3.3% | +35.4% | -22.3% | – | – | – | |
| GRFSGrifols, S.A. | $7.13B | -0.4% | – | 38.4% | 15.2x | 10.0x | – | |
| 同行中位数 | – | – | +19.7% | 35.1% | 23.4x | 12.7x | 25.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。